ZEB2 suppression induces aberrant differentiation of human AML cells. (A) (Left) Flow cytometric analysis of side-scatter profiles and the expression of CD11b, CD13, CD14, CD16, and CD16 in HL-60 and THP-1 cells infected with ZEB2-531 and its seed control (ZEB2-531-sc) at day 6. (Right) Quantification of results from the left shown as average fold change of marker expression comparing ZEB2 shRNA (ZEB2-531) and seed control (ZEB2-531-sc). Error bars, SD (n = 3). (B) Representative May-Grunwald-Giemsa staining of HL-60 and THP-1 cells at day 10 after infection. Original magnification ×200; original magnification for insets ×400. (C) Flow cytometric analysis of BrdU incorporation in HL-60 and THP-1 cells at day 6 after infection.